Pharming Group Nv (PHAR)
NASDAQ:PHAR
Want to see PHAR full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.06Last Year’s EPS
0.06Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a constructive outlook driven by strong Joenja growth, meaningful pipeline and regulatory catalysts, and demonstrated cost discipline with positive operating cash flow. These positives offset near‑term revenue variability driven mainly by expected RUCONEST inventory normalization, strategic market exits and short‑term competitive pressure. Management reaffirmed full‑year guidance and highlighted multiple upcoming clinical and commercial events that could drive upside.Company Guidance
Reaffirmed Full-Year Revenue Guidance
Q1 revenues were $72.4M (down 8% YoY) but management reaffirmed full-year 2026 revenue guidance of $405M–$425M, implying growth of ~8%–13% YoY and signaling confidence in near‑term recovery and product momentum.
Strong Joenja Commercial Momentum
Joenja revenue grew 34% YoY to $14.1M in Q1; U.S. paid patients reached 127 (+25% YoY) with a U.S. fill rate of 85%. Management expects further acceleration from upcoming launches in Germany and Japan and pediatric label expansion in the U.S.
RUCONEST Franchise Durability and New Prescriber/Enrollment Growth
RUCONEST remains a strategic cash engine despite headline declines: added ~50 new patient enrollments and 23 new prescribers in Q1; the majority of existing RUCONEST patients have remained on therapy nine months after the launch of a new oral competitor.
Pipeline and Regulatory Progress
Key clinical and regulatory catalysts ahead: resubmission of Joenja pediatric sNDA for highest doses in April with FDA decision expected in ~6 months; planned summer sNDA for lower doses; two Phase II readouts for leniolisib in higher‑prevalence PIDs expected in H2 2026; napazimone registrational study expected to complete enrollment in 2026 with readout in 2027.
Disciplined Cost Management and Positive Operating Cash Flow
Total operating expenses down 9% YoY (adjusted flat excluding nonrecurring 2025 acquisition costs). Q1 operating cash flow was positive at $2M. Cash and marketable securities totaled $171.8M. Company expects gross margin ~90% and reiterated Opex guidance of $330M–$335M including $60M incremental R&D.
PHAR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PHAR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $16.40 | $12.00 | -26.83% |
Mar 12, 2026 | $15.88 | $15.14 | -4.66% |
Nov 06, 2025 | $13.18 | $14.70 | +11.53% |
Jul 31, 2025 | $10.09 | $11.11 | +10.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pharming Group Nv (PHAR) report earnings?
Pharming Group Nv (PHAR) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Pharming Group Nv (PHAR) earnings time?
Pharming Group Nv (PHAR) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAR EPS forecast?
PHAR EPS forecast for the fiscal quarter 2026 (Q2) is 0.06.